Bionomics IPO Presentation Deck
Offering Summary
Issuer
Ticker / Exchange
Gross Proceeds
Option to Purchase ADSS
Use of Proceeds
Lock-Up Period
Active Bookrunners
Expected Pricing
Bionomics
PTSD = Post-Traumatic Stress Disorder
Represents ADS ratio of 180
Bionomics Limited
BNOX / Nasdaq Global Market
-$25.0 million (1,620,000 ADS, 100% primary, excluding over-allotment)
-$3.75 million (15% of the offering ADSS)
To advance BNC210 into a Phase 2 trial for the acute treatment of Social Anxiety Disorder (SAD), including
the initiation and completion of the planned Phase 2 PREVAIL clinical trial
H
The continued development of BNC210 for the treatment of PTSD, including completion of the ongoing
Phase 2b ATTUNE clinical trial
E
The completion of chemistry, manufacturing and controls, long term safety and non-clinical pharmacology
studies necessary to support Phase 3 pivotal trials of BNC210 for the treatment of SAD and PTSD
Working capital and other research and development and general corporate purposes
180 days for the Company, directors, executive officers and certain shareholders
Evercore ISI, William Blair
Week of December 13, 2021
3View entire presentation